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Diagnosis in vascular dementia, applying ‘Cochrane diagnosis rules’ to ‘dementia diagnostic tools’  
“Doctor, will I get dementia?” is a frequent question in the memory clinic.  Unfortunately, current 
assessment tools are often unable to give the patient a satisfactory answer.  In clinical practice and 
in research, making an early diagnosis of dementia, especially vascular dementia, is challenging.[1]  A 
particular issue is that the traditional ‘gold standard’ diagnostic assessment is neuropathology, 
which is only really possible in post-mortem samples.[2]  Advances in technology are helping us 
overcome this problem and increasingly sophisticated neuroimaging can give us impressive 
visualisations of cerebral structure and function in-vivo.   
In this issue of Clinical Science, Biesbroek and colleagues describe recent work on Magnetic 
Resonance Imaging (MRI) based cerebral lesion location and its association with cognitive decline.[3]  
The authors conclude that diagnostic neuroimaging in dementia should shift from whole brain 
evaluation to focussed quantitative analysis of strategic brain areas.  The review provides a 
fascinating insight into the evolution of the lesion location concept from single case-study through to 
lesion-symptom maps based on quantitative analysis of images from large observational cohorts.  
The authors speculate on the clinical applications that might follow from lesion-symptom mapping in 
the next few years.  Their most immediate ambition for the technique is “to improve the diagnostic 
work-up of memory clinic patients with SVD (small vessel disease)”.  Looking further ahead, they 
hope that the techniques they describe may have prognostic utility, predicting decline in individual 
cognitive domains and treatment response by enabling the tailoring of treatments to the 
neurochemistry of affected tracts and regions.  
In the field of vascular dementia, or indeed dementia generally, where standard assessment is an 
imperfect guide to diagnosis and prognosis, it is tempting to embrace new tools in the hope that any 
development must be better than current practice.  However, there is a risk that enthusiasm for new 
technologies can outpace the data.[4]  Advances in technology will almost certainly transform the 
clinic cognitive work-up, but new assessment tools should be scutinised with the same rigour we 
would expect to be applied to a new treatment.  In the Cochrane Dementia and Cognitive 
Improvement Group (CDCIG), we strive to collate, synthesise and critically appraise the growing 
literature around new dementia biomarkers.[5]  Since the aim of biomarker-based tests is often to 
identify patients in earlier stages of disease than has previously been possible, we have, in this 
context, considered early diagnosis to be inseparable from prognosis. When the clinical question we 
seek to answer is  'which patients will develop dementia?', then the diagnostic gold standard is the 
longitudinal outcome.[6]  Informed by our systematic reviews, we have produced best practice 
guidance for the conduct and reporting of studies evaluating potential diagnostic tests for dementia 
.[7,8]  
For randomised control trials, the standardised approach to reporting outlined in the CONSORT 
(Consolidated Standards of Reporting Trials) statement and checklist has helped raise awareness of 
methodological and reporting standards.[9]  For many scientific journals a completed CONSORT 
checklist is now mandatory when submitting a paper describing a trial.  A similar set of reporting 
guidelines for diagnostic test accuracy studies is available in the STARD (Standards for Reporting 
Diagnostic Accuracy) guideline.[10]  While STARD is a useful tool, applying these recommendations 
to studies in dementia can prove problematic.[11]  To make a resource more suited to those working 
in the dementia field, a STARD extension specific to dementia test accuracy studies is now available 
(STARDdem).[7]  Although primarily a reporting guideline, STARDdem materials can also highlight 
critical issues at the earlier stages of study design and execution. Some issues which may be of 
particular importance to future studies of lesion localisation in SVD are the representativeness of the 
sample, selection of test thresholds, patient flow and analysis methods. 
Representativeness of study samples: There is sometimes an apparent disconnect between the 
participants included in dementia biomarker studies and the population of interest.  For example, 
although early onset monogenic dementias such as CADASIL (Cerebral Autosomal Dominant 
Arteriopathy with Subcortical Infarcts and Leucoencephalopathy) offer an excellent opportunity to 
study a pure dementia phenotype, these rare syndromes are not representative of the older adults 
with memory problems that we see in practice.[12]  For an assessment of a biomarker to have 
external validity the sampling frame should approximate to the population in which the test will be 
used.  Capturing the ‘messy reality’ of the patients seen in secondary care memory services, who 
often have substantial comorbidity and frailty, in a controlled research study is challenging, but is a 
vital step before changes to practice can be recommended.[13]  In this context, Biesbroek and 
colleagues' point out that assessment of regional lesion volumes should be complemented by 
biomarker tests assessing other possible causes of brain injury and neurodegeneration.  Any single 
biomarker test may be markedly less informative in older patients with multiple brain pathologies 
than in younger patients with 'purer' neuropathologies. 
Also important for external validity is a move away from the case-control methods used in many of 
the studies in the Biesbroek review.  The case control approach is acceptable for initial validation 
work, but has many inherent limitations.  It typically manipulates the occurrence of the condition of 
interest (in this case vascular dementia) to enrich the sample with more ‘cases’.  As the resulting 
sample does not have the natural population frequency of disease, no comment can be made on 
metrics that are dependent on disease prevalence such as predictive values.[13]  Further, the case-
control methodology, by tending to favour phenotypic extremes such as healthy controls with no 
comorbidity versus patients with frank dementia, artificially inflates measures of test accuracy and 
does not tell us about the patients of greatest interest – those in whom the clinical diagnosis is 
uncertain.[14] 
A final step to consider around external validity is the need for replication of results in independent 
cohorts.  It is notable that many of the studies included in the Biesbroek review come from the same 
academic groups.  This is not a criticism, as early phase work using cutting edge technology will 
necessarily be restricted to specialist centres.  However, before recommendations can be made 
around general usage of a test, the positive results seen in early adopting centres need to be 
confirmed in work from other international sites.   
 
Test thresholds and patient flow: STARD (and STARDdem)[7,10] guidance emphasises the need to 
report potential sources of bias which can challenge the internal validity of diagnostic test accuracy 
studies. Some of the issues, such as recruitment and blinding, are well known. However, others may 
be less intuitive, including the importance of describing test thresholds and patient flow. 
For most tests, the output is a series of data that are then assessed to give a binary output of 
disease/no disease status.  To make this classification, a threshold is set beyond which the subject is 
said to be ‘test positive’. In Biesbrock's clinical example, this would be the lesion volume in the 
relevant strategic tract which is considered sufficient to count as an explanation for the patient's 
symptoms. If test thresholds are not pre-specified in a diagnostic study, then it is tempting to use the 
threshold that gives the most impressive results and thus artificially increases test accuracy.  If 
various centres all use differing thresholds then comparison becomes impossible.   
For any test, not all subjects will complete the test and give usable test data.  For novel 
neuroimaging sequences with potentially long image acquisition times , test non-completion may be 
a particular concern.  Test accuracy reporting should allow for an ‘intention to diagnose’ approach, 
so that it is immediately apparent how many subjects did not complete the protocol or gave 
indeterminate/ unusable data.[15]  Simply excluding these test ‘drop-outs’ from the analysis will, 
again, artificially improve apparent test accuracy.[16]  
 
Analysis methods - moving beyond correlations: There are many potential approaches to the 
quantitative description of how a test performs.  A common analysis is to describe correlation 
between test data and an outcome of interest.  Many of the papers included in the Biesbroek review 
describe correlation of lesion pathology with scores on a neuropsychological battery.  Correlation-
based analyses are suitable for early phase work with a new diagnostic test.  However, for 
understanding clinical utility, correlation is a fairly blunt instrument and other statistical approaches 
are preferred.   
There is no perfect method for describing test properties.  While the paired values of sensitivity and 
specificity are the most commonly used measures of test accuracy, metrics such as predictive value, 
which quantify the probability of presence/absence of the target condition given a particular test 
result,  may have greater clinical utility for assessment of an individual patient.[17]  The reporting of 
a 2x2 table, cross-classifying test results with disease status, allows for calculation of 
sensitivity/specificity, predictive values and many other test metrics and is recommended for all 
papers describing the properties of diagnostics tests.   
Test accuracy metrics should not be interpreted in isolation.  Increasingly we are recognising the 
importance of describing the full test-to-treatment pathway.[18]  Performance of a test can be 
associated with various direct and indirect effects.  Test accuracy is not synonymous with clinical 
effectiveness and an accurate test does not necessarily result in improved patient outcomes.  A 
particular concern when testing for a neurodegenerative condition such as dementia is the potential 
consequence of test error.  If a novel imaging test gives a patient with early or subclinical dementia a 
false negative result, this is unfortunate, but probably of relatively little consequence.  The natural 
history of preclinical dementia states is highly variable, at present we have no proven preventative 
treatment and the true diagnosis will emerge when the subject becomes symptomatic.  However, a 
misdiagnosis of incipient dementia in a healthy individual will likely have substantial negative effects 
on their psychological health and lead to potentially inappropriate resource use through onward 
referrals, further testing and follow-up.  Many of the cerebrospinal fluid biomarkers tests for 
dementia, for example, have a false positive rate that, although modest, may still be too high for 
routine use in clinical practice.[19] 
Moving beyond accuracy, aspects of test evaluation including test feasibility and acceptability are 
important to understand before advocating routine use of a test.  To date these metrics have been 
rarely described for dementia biomarkers.  Where a new test is being considered in favour of an 
existing approach it can be useful to describe the incremental benefit over standard practice.  For 
example, in a recent study looking at imaging biomarkers, the authors found reasonable test 
accuracy of the biomarkers, but when considered in the context of standard memory testing there 
was little additional value of these sophisticated tests (calculated using a net re-classification 
index).[20] 
The next generation of neuroimaging biomarker studies: These comments are not intended as 
criticisms of the existing research on imaging biomarkers, but should draw attention to the 
challenges facing future studies.  For lesion location work, Biesbroek’s review demonstrates that 
proof of concept is now established.  The next steps towards clinical utility should build on the 
considerable experience accumulated in studies of biomarkers for the diagnosis of Alzheimer's 
disease.  Proposed revisions of diagnostic criteria for dementia place increasing emphasis on 
biomarkers.[21]  We argue here that enthusiasm for the new must be tempered with a keen critical 
appraisal in order to maximise the benefits of new technologies while avoiding premature adoption 
of diagnostic strategies that are no better than standard approaches or even have potential 
unintended harms.  
 
Dr Quinn and McCleery are the joint coordinating editors of the Cochrane Dementia and Cognitive 
Improvement Group (http://dementia.cochrane.org/) and have published guidelines and best 
practice statements on dementia test accuracy studies.  
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